Drug intelligence / Profile preview

99mTc-HYNIC-Anti-MRC2

Development stage
Preclinical
Lead developer
Huazhong University of Science and Technology
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

99mTc-HYNIC-Anti-MRC2 is a technetium-99m (99mTc)-labeled monoclonal antibody imaging probe developed for single-photon emission computed tomography (SPECT) imaging. It specifically targets Mannose Receptor C Type 2 (MRC2), also known as urokinase plasminogen activator receptor-associated protein (uPARAP) or Endo180, which is upregulated in various human tumors and cancer-associated fibroblasts (CAFs). The probe is synthesized by conjugating an anti-MRC2 monoclonal antibody with the bifunctional chelator succinimidyl 6-hydrazinonicotinate hydrochloride (SHNH/HYNIC) and radiolabeling it with 99mTc. It is designed for noninvasive visualization and quantitative detection of tumoral MRC2 expression, supporting the diagnosis and potentially guiding targeted radionuclide therapy for MRC2-positive tumors.

Other names
99mTc-HYNIC-anti-MRC2
02

Identity

Drug type
Antibody-Based Therapeutics
Modality
Monoclonal AntibodiesAntibody-Radionuclide ConjugatesGamma Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
breast cancer and precursor lesionsPreclinicalActive
glioblastoma, IDH-wildtypePreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Huazhong University of Science and TechnologyLead developer
07

Competitive landscape

Drugs in the lead indication
1,053

Lead indication: breast cancer and precursor lesions

Most advanced in the lead indication

  1. cyclophosphamideApproved
  2. epirubicinApproved
  3. eribulinApproved
  4. fludeoxyglucose f 18Approved
  5. fluorouracilApproved

Beyond the preview

Go deeper on 99mTc-HYNIC-Anti-MRC2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-HYNIC-Anti-MRC2.

Work on 99mTc-HYNIC-Anti-MRC2? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call